Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093167 · ClinicalTrials.gov registry record · Phase 2
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 10
- Study locations
NCT04093167: Recruiting Phase 2 study of Lung Cancer, sponsored by Canadian Cancer Trials Group.
NCT04093167 is a Phase 2 study of Lung Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 230 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04093167, a Phase 2 study of Lung Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 10
- Study locations
Study Summary
The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.
Primary Outcome
Molecular response will be assessed by measuring changes in ctDNA levels in plasma
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (10)
Ontario
- Health Sciences North - Greater Sudbury
- Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
- Kingston Health Sciences Centre - Kingston
- Ottawa Hospital Research Institute - Ottawa
- Algoma District Cancer Program - Sault Ste. Marie
- University Health Network - Toronto
Illinois
- The University of Chicago Medical Center - Chicago
Maryland
- The Sidney Kimmel Comprehensive Cancer Centre - Baltimore
British Columbia
- BCCA - Vancouver - Vancouver
Quebec
- The Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2020-05-26 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
What NCT04093167 shows while recruiting
NCT04093167 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT04093167 lists 10 locations in 5 states (Ontario, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT04093167 about?
NCT04093167 is a clinical study titled "Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer". The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pe...
What is the current status of trial NCT04093167?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2020-05-26. Estimated completion is 2027-07-30.
What conditions does trial NCT04093167 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT04093167?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04093167?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04093167 being conducted?
This trial has 10 study locations across Illinois, Maryland, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04093167's enrollment target sits among peer trials
230 123rd of 409 higher than 287 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI